Imatinib mesylate
-
API Product :
Imatinib mesylate
-
CEP :
¤
-
WCC :
?
-
Therapeutic Use :
Antineoplastics
-
Originator :
Novartis
-
CAS No. :
493.603 g/mol
-
Trade Name. :
GLEEVEC
-
Molecular Weight :
493.603 g/mol
-
Molecular Formula :
C29H31N7O
Application
This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.
General Description
Imatinib, sold under the brand names Gleevec among others, is a medication used to treat cancer.[1] Specifically, it is used for chronic myelogenous leukemia(CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome.[1] It is taken by mouth.[1] Common side effects include vomiting, diarrhea, muscle pain, headache, and rash.[1] Severe side effects may include fluid retention, gastrointestinal bleeding, bone marrow suppression, liver problems, and heart failure.[1] Use during pregnancy may result in harm to the baby.[1] Imatinib works by stopping the Bcr-Abl tyrosine-kinase.[1] This can slow growth or result in programmed cell death of certain types of cancer cells.